This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Germany's Merck to Buy Millipore for $7.2B

Updated to include premarket stock price

BILLERICA, Mass. ( TheStreet) -- Millipore (MIL - Get Report) has reached an agreement to be acquired by Germany's Merck for $107 a share in cash, or a total of $7.2 billion, including debt.

Merck's agreement to buy Millipore, a maker of biotech equipment, follows reports last week that Millipore was in talks to be acquired by Thermo Fisher Scientific (TMO - Get Report). The deal's value was reported as $6 billion, excluding debt.

"This transaction is very attractive to shareholders, customers and employees of both companies," said Karl-Ludwig Kley, chairman of Merck's executive board of Merck, in a statement. "This is a combination with an excellent strategic fit, which will allow us to cover the entire value chain for our pharma and biopharma customers, offering integrated solutions beyond chemicals."

Merck and Millipore said the merger would create a $2.9 billion partnership in the life sciences sector, "achieving significant scale in high-margin specialty products with an attractive growth profile."

Merck's offer is a 13.3% premium to Millipore's closing price Friday of $94.41. Millipore shares closed Friday, Feb. 19, the last day before news of a deal broke, at $71.34.

Millipore shares were changing hands at $105.09 in premarket trading Monday.

Merck anticipates that the transaction will be completed in the second half of 2010. Approval is needed from Millipore shareholders.

-- Reported by Joseph Woelfel in New York.

Follow TheStreet.com on Twitter and become a fan on Facebook.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
MIL $3.18 7.80%
TMO $127.91 2.12%
AAPL $112.92 2.94%
FB $89.73 2.91%
GOOG $637.61 1.43%

Markets

Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs